FDA Grants Breakthrough Therapy Designation to Pfizer ’s Group B Streptococcus Vaccine Candidate to Help Prevent Infection in Infants Via Immunization of Pregnant Women

NEW YORK--(BUSINESS WIRE) September 07, 2022 -- Pfizer Inc. (NYSE:PFE) today announced that its investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designation from the U.S. Food and Drug...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials